TPI Schedules Test Runs at Jiangchuan Macrolide Facility by End of July
CHENGDU, China, July 8, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced that its 250-ton Jiangchuan Macrolide facility (JCM) is scheduled for its manufacturing test runs by the end of July.
The test runs prepare the production lines for the final Good Manufacturing Practice (GMP) certification process by conducting a series of operations and tests under actual or simulated operating conditions to verify its performance, efficiency, reliability and safety of the Azithromycin API manufacturing at JCM.
The successful completion of the test runs will be immediately followed by the GMP certification at JCM.
Good Manufacturing Practice (GMP), widely adopted worldwide, provide guidelines covering the manufacture and testing of pharmaceuticals and active pharmaceutical ingredients, diagnostics, foods, pharmaceutical products, and medical devices with the basic concepts that safeguard the health of the patient, producing a good quality medicine, medical devices or active pharmaceutical products. GMP guidelines are a series of general principles that are mandated during manufacturing. The context of GMP covers plant and equipment operation, personnel training, quality management, product safety and stability along with other aspects that ensure the quality the product (www.sfda.gov.cn, Chinese version).
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingred